Cocrystal Pharma, Inc. (COCP) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-55.3%

$0.47

vs $1.06 price

Levered DCF

$0.49

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

-108.13

Distress zone

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-1.26×	-1.17×	-905.26×	-0.41×	-4.22×	-8.12×	-0.38×	-2.06×
P/B	1.75×	2.16×	0.63×	0.4×	0.77×	1.49×	0.71×	1.51×
P/S	0×	0×	0×	0×	0×	38.87×	2.79×	0×
EV / EBITDA	-0.65×	-0.72×	0.38×	1.18×	-0.13×	-4.86×	-5.32×	-1.57×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	-199.6%	39.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	-476.0%	-737.4%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	-479.0%	-733.8%	0.0%
Current ratio	3.68×	4.77×	8.92×	33.04×	38.4×	25.05×	3.62×	1.89×
Debt / equity	0.24×	0.19×	0.07×	0.01×	0.01×	0.01×	0.03×	0×
Interest coverage	0×	0×	0×	-19,414.5×	-3,555.25×	-1,198.25×	-2,547.68×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-139.5%	-183.8%	-68.2%	-98.2%	-18.3%	-18.4%	-187.4%	-73.3%
Return on invested capital	-115.1%	-157.8%	-65.7%	-97.4%	-18.2%	-18.1%	-182.5%	-73.3%
Return on assets	-90.9%	-130.1%	-57.5%	-95.1%	-17.9%	-17.8%	-168.8%	-71.5%
Free cash flow yield	-74.2%	-80.3%	-89.1%	-135.5%	-21.3%	-12.9%	-9.3%	-8.2%
Earnings yield	-79.9%	-85.2%	-108.3%	-244.6%	-23.7%	-12.3%	-262.9%	-48.6%
Enterprise value	$5.5M	$12.5M	-$7.9M	-$21M	$1.8M	$45.9M	$11.7M	$98.4M
Net debt / EBITDA	0.65×	0.46×	1.17×	2.08×	4.16×	3.44×	2.99×	0.04×
Cash conversion cycle (days)	-64	-45	-29	-18	-24	61	-102	-4,497